Cargando…

GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2

Mutations in leucine-rich repeat kinase 2 (LRRK2) comprise the most common cause of familial Parkinson's disease (PD), and sequence variants modify risk for sporadic PD. Previous studies indicate that LRRK2 interacts with microtubules (MTs) and alters MT-mediated vesicular transport processes....

Descripción completa

Detalles Bibliográficos
Autores principales:	Blanca Ramírez, Marian, Ordóñez, Antonio Jesús Lara, Fdez, Elena, Madero-Pérez, Jesús, Gonnelli, Adriano, Drouyer, Matthieu, Chartier-Harlin, Marie-Christine, Taymans, Jean-Marc, Bubacco, Luigi, Greggio, Elisa, Hilfiker, Sabine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5886193/ https://www.ncbi.nlm.nih.gov/pubmed/28453723 http://dx.doi.org/10.1093/hmg/ddx161

Ejemplares similares

Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation
por: Madero-Pérez, Jesús, et al.
Publicado: (2018)

LRRK2 Phosphorylation, More Than an Epiphenomenon
por: Marchand, Antoine, et al.
Publicado: (2020)

Centrosomal cohesion deficits as cellular biomarker in lymphoblastoid cell lines from LRRK2 Parkinson's disease patients
por: Fernández, Belén, et al.
Publicado: (2019)

A Link between Autophagy and the Pathophysiology of LRRK2 in Parkinson's Disease
por: Gómez-Suaga, Patricia, et al.
Publicado: (2012)

LRRK2 and neuroinflammation: partners in crime in Parkinson’s disease?
por: Russo, Isabella, et al.
Publicado: (2014)

RAB7L1-Mediated Relocalization of LRRK2 to the Golgi Complex Causes Centrosomal Deficits via RAB8A
por: Madero-Pérez, Jesús, et al.
Publicado: (2018)

LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson’s Disease, Where Do We Stand?
por: Taymans, Jean-Marc, et al.
Publicado: (2016)

LRRK2 Kinase Activity Is Dependent on LRRK2 GTP Binding Capacity but Independent of LRRK2 GTP Binding
por: Taymans, Jean-Marc, et al.
Publicado: (2011)

Protocol to measure centrosome cohesion deficits mediated by pathogenic LRRK2 in cultured cells using confocal microscopy
por: Fdez, Elena, et al.
Publicado: (2023)

The LRRK2 signaling network converges on a centriolar phospho-Rab10/RILPL1 complex to cause deficits in centrosome cohesion and cell polarization
por: Lara Ordóñez, Antonio Jesús, et al.
Publicado: (2022)

A Phosphosite Mutant Approach on LRRK2 Links Phosphorylation and Dephosphorylation to Protective and Deleterious Markers, Respectively
por: Marchand, Antoine, et al.
Publicado: (2022)

Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells
por: Goveas, Liesel, et al.
Publicado: (2021)

The G2019S variant of leucine-rich repeat kinase 2 (LRRK2) alters endolysosomal trafficking by impairing the function of the GTPase RAB8A
por: Rivero-Ríos, Pilar, et al.
Publicado: (2019)

PAK6 Phosphorylates 14-3-3γ to Regulate Steady State Phosphorylation of LRRK2
por: Civiero, Laura, et al.
Publicado: (2017)

RAB8, RAB10 and RILPL1 contribute to both LRRK2 kinase–mediated centrosomal cohesion and ciliogenesis deficits
por: Lara Ordónez, Antonio Jesús, et al.
Publicado: (2019)

The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinson’s Disease
por: Rideout, Hardy J., et al.
Publicado: (2020)

Trafficking of the glutamate transporter is impaired in LRRK2-related Parkinson’s disease
por: Iovino, Ludovica, et al.
Publicado: (2022)

Pathogenic LRRK2 regulates centrosome cohesion via Rab10/RILPL1-mediated CDK5RAP2 displacement
por: Fdez, Elena, et al.
Publicado: (2022)

Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation
por: Lobbestael, E., et al.
Publicado: (2016)

The Parkinson's Disease Associated LRRK2 Exhibits Weaker In Vitro Phosphorylation of 4E-BP Compared to Autophosphorylation
por: Kumar, Azad, et al.
Publicado: (2010)

Cryo-EM analysis of homodimeric full-length LRRK2 and LRRK1 protein complexes
por: Sejwal, Kushal, et al.
Publicado: (2017)

Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity
por: Fernández, Belén, et al.
Publicado: (2022)

Alterations in the LRRK2-Rab pathway in urinary extracellular vesicles as Parkinson’s disease and pharmacodynamic biomarkers
por: Taymans, Jean-Marc, et al.
Publicado: (2023)

Functional Analyses of Two Novel LRRK2 Pathogenic Variants in Familial Parkinson′s Disease
por: Coku, Ilda, et al.
Publicado: (2022)

LRRK2 phosphorylates pre-synaptic N-ethylmaleimide sensitive fusion (NSF) protein enhancing its ATPase activity and SNARE complex disassembling rate
por: Belluzzi, Elisa, et al.
Publicado: (2016)

Parkinson’s Disease–Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance
por: Streubel-Gallasch, Linn, et al.
Publicado: (2021)

Rab GTPases in Parkinson's disease: a primer
por: Lara Ordóñez, Antonio Jesús, et al.
Publicado: (2021)

Distinct Roles for RAB10 and RAB29 in Pathogenic LRRK2-Mediated Endolysosomal Trafficking Alterations
por: Rivero-Ríos, Pilar, et al.
Publicado: (2020)

Targeting the Autophagy/Lysosomal Degradation Pathway in Parkinson´s Disease
por: Rivero-Ríos, Pilar, et al.
Publicado: (2016)

Parkinson’s disease and immune system: is the culprit LRRKing in the periphery?
por: Greggio, Elisa, et al.
Publicado: (2012)

Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism
por: Taymans, Jean-Marc, et al.
Publicado: (2014)

Ceramides in Parkinson’s Disease: From Recent Evidence to New Hypotheses
por: Plotegher, Nicoletta, et al.
Publicado: (2019)

Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease?
por: Greggio, Elisa, et al.
Publicado: (2011)

LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex
por: Cirnaru, Maria D., et al.
Publicado: (2014)

A Novel GTP-Binding Inhibitor, FX2149, Attenuates LRRK2 Toxicity in Parkinson’s Disease Models
por: Li, Tianxia, et al.
Publicado: (2015)

Role of LRRK2 in the regulation of dopamine receptor trafficking
por: Rassu, Mauro, et al.
Publicado: (2017)

Editorial: LRRK2—Fifteen Years From Cloning to the Clinic
por: Rideout, Hardy, et al.
Publicado: (2022)

Progress in LRRK2-Associated Parkinson’s Disease Animal Models
por: Seegobin, Steven P., et al.
Publicado: (2020)

Upstream deregulation of calcium signaling in Parkinson’s disease
por: Rivero-Ríos, Pilar, et al.
Publicado: (2014)

A homologue of the Parkinson’s disease-associated protein LRRK2 undergoes a monomer-dimer transition during GTP turnover
por: Deyaert, Egon, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8g69ce0nv4ic64a7hq5pvck57i